|
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical research trials and Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer. Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer clinical trial. Test subjects typically receive the most effective healthcare possible for their Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer  Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
For Condition: adult primary hepatocellular carcinoma,recurrent adult primary liver cancer,localized resectable adult primary liver cancer
Status: Recruiting
Sponsor(s): Washington University Siteman Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment. PURPOSE: Diagnostic trial to compare the effectiveness of carbon-11 acetate PET with that of fludeoxyglucose F 18 PET in detecting cancer in patients who have liver cancer.
Details: OBJECTIVES: - Determine, preliminarily, the relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18 for detection of hepatocellular carcinoma (HCC) in patients with known or highly suspected HCC. - Determine whether these PET scans identify additional sites of disease not detected by conventional imaging in these patients. - Determine, preliminarily, the impact of these PET scans on the management of these patients. OUTLINE: This is a nonrandomized, pilot study. Patients undergo carbon-11 acetate-positron emission tomography (PET) over approximately 1 hour followed by fludeoxyglucose F 18-PET over approximately 2 hours. Any positive findings noted by the PET scans are confirmed by repeat CT scan, MRI, and/or bone scintigraphy at approximately 6 months after the PET scans are performed. Biopsy confirmation is performed where indicated. Patients with discrepency between the PET scans and conventional imaging OR with unclarified PET scan results are followed at 6 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 18 months.
Eligibility:
Study Type: Interventional, Diagnostic
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Diagonosis of one of the following: - Histologically confirmed hepatocellular carcinoma (HCC) - Stage I or stage II disease by conventional staging - Prior HCC with a new primary tumor OR recurrent HCC allowed - Clinically documented cirrhosis meeting at least one of the following criteria: - Alpha-fetoprotein > 200 mg/dL - Contrast-enhancing tumor mass 1 cm by CT scan or MRI - Tumor mass confirmed by arteriography - Scheduled for routine clinical fludeoxyglucose F 18-positron emission tomography PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Not specified Life expectancy - Not specified Hematopoietic - Not specified Hepatic - See Disease Characteristics Renal - Not specified Other - No poorly controlled diabetes mellitus (fasting blood glucose > 200 mg/dL) - No other malignancy within the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
WilliamChapman, Study Chair, Washington University Siteman Cancer Center
Siteman Cancer Center *Recruiting*
St. Louis, Missouri, 63110
United States
Recruiting William Chapman 314-361-7792
Additional Information:
Study ID Numbers: CDR0000358907; WU-03-0771
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00081094
Other Localized Resectable Adult Primary Liver Cancer Studies:
1. Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
2. SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
3. Epirubicin and Thalidomide in Treating Patients With Liver Cancer
4. TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
5. Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Related Studies:
Other localized resectable adult primary liver cancer Clinical Trials
Other Missouri Clinical Trials
Other St. Louis Clinical Trials
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
|
|
|
|
|
|
|
|
